8-K: Galera Therapeutics Announces 2023 Financial Results and Strategic Review Amidst Clinical Setbacks

Galera Therapeutics reported its 2023 financial results, highlighted by cost-cutting measures and a strategic review following regulatory setbacks for its lead drug candidate.

Summary

• Galera Therapeutics announced its financial results for the fourth quarter and full year of 2023, alongside corporate updates.
• The company is evaluating strategic options to maximize shareholder value, which could include a potential development path for avasopasem or even the dissolution of the company.
• A significant workforce reduction of approximately 70% was implemented in August 2023 to reduce operational costs.
• Galera engaged Stifel, Nicolaus & Company, Inc. in October 2023 to assist in reviewing strategic alternatives.
• The FDA issued a Complete Response Letter (CRL) in August 2023 for the avasopasem NDA, requiring an additional Phase 3 trial for resubmission.
• The company halted the Phase 2b GRECO-2 trial for rucosopasem in pancreatic cancer and the Phase 1/2 GRECO-1 trial for non-small cell lung cancer due to negative futility analyses.
• Research and development expenses decreased to $3.2 million in Q4 2023 from $8.1 million in Q4 2022, and to $24.1 million for the full year 2023 from $31.0 million in 2022.
• General and administrative expenses decreased to $2.0 million in Q4 2023 from $5.0 million in Q4 2022, but increased to $22.8 million for the full year 2023 from $20.2 million in 2022.
• Galera reported a net loss of $(5.6) million, or $(0.10) per share, for Q4 2023, compared to a net loss of $(16.2) million, or $(0.58) per share, for Q4 2022.
• The company reported a net loss of $(59.1) million, or $(1.33) per share, for the full year 2023, compared to a net loss of $(62.2) million, or $(2.30) per share, for 2022.
• As of December 31, 2023, Galera had cash and cash equivalents of $18.3 million, which is expected to fund operations into the second quarter of 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the regulatory setback, clinical trial failures, and the possibility of company dissolution. While cost-cutting measures and a cash runway extension are positive, they are overshadowed by the significant challenges the company faces.

Positives

• The company has significantly reduced operating expenses through a workforce reduction and halting of certain development programs.
• Galera's cash runway extends into the second quarter of 2025.
• Data from the ROMAN trial showed a 50% reduction in the incidence of chronic kidney disease with avasopasem compared to placebo.
• The company has engaged a financial advisor to explore strategic alternatives to maximize shareholder value.

Negatives

• The FDA issued a Complete Response Letter (CRL) for avasopasem, requiring an additional Phase 3 trial.
• The company halted Phase 2b and Phase 1/2 trials for rucosopasem due to futility analyses.
• Galera is exploring strategic options that could lead to the dissolution of the company.
• The company incurred restructuring-related charges of $2.3 million in the third quarter of 2023.

Risks

• Galera faces the risk of not securing additional funding or a strategic partnership, which could lead to ceasing operations.
• The company's future is uncertain due to the need for an additional Phase 3 trial for avasopasem and the failure of rucosopasem trials.
• There is a risk that the company may not be able to enter into any desired strategic alternative or partnership on a timely basis, on acceptable terms, or at all.
• The company's common stock could be delisted from The Nasdaq Global Market.
• Galera is dependent on the success of its product candidates, particularly avasopasem, and faces risks related to clinical trials, regulatory approvals, and commercialization.

Future Outlook

Galera expects its existing cash and cash equivalents will fund operations into the second quarter of 2025. The company is exploring strategic alternatives to maximize shareholder value, including a potential development path for avasopasem, which could ultimately result in the dissolution of the company.

Management Comments

• As a result of last years FDA request for a second Phase 3 trial to support the avasopasem NDA, we have implemented key measures to extend our cash runway and assess strategic alternatives, said Mel Sorensen, M.D., Galeras President and CEO.
• We recognize that the decision to discontinue our GRECO trials was challenging for our team and our clinical investigators, but we believe it was the appropriate decision, following the negative futility analysis in the pancreatic trial.
• We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.

Industry Context

The biopharmaceutical industry is highly competitive and faces significant regulatory hurdles. Galera's situation reflects the challenges of drug development, where clinical trial failures and regulatory setbacks can lead to significant financial and strategic shifts. The company's focus on strategic alternatives is not uncommon for companies facing such challenges.

Comparison to Industry Standards

• Galera's situation is comparable to other small-cap biotech companies that have faced regulatory setbacks and clinical trial failures, such as Odonate Therapeutics, which also had to discontinue its lead drug candidate and explore strategic alternatives.
• The need for an additional Phase 3 trial for avasopasem is similar to situations faced by other companies where initial trial data was deemed insufficient by regulatory agencies, such as the FDA's request for additional data for Sarepta Therapeutics' Duchenne muscular dystrophy drug.
• The 70% workforce reduction is a drastic measure, but it is not uncommon for biotech companies facing financial difficulties, similar to the restructuring seen at companies like Agenus and Verastem Oncology.
• The exploration of strategic alternatives, including a potential dissolution, is a common outcome for companies that have exhausted their development options, similar to the path taken by companies like OncoMed Pharmaceuticals.

Stakeholder Impact

• Shareholders face significant uncertainty due to the potential dissolution of the company and the need for an additional Phase 3 trial for avasopasem.
• Employees have been significantly impacted by the 70% workforce reduction.
• Patients may experience delays in accessing potential treatments for radiotherapy-induced toxicities and cancer.

Next Steps

• The company will continue to explore strategic alternatives to maximize shareholder value.
• Galera will assess potential options for the development of avasopasem, including the possibility of conducting an additional Phase 3 trial.
• The company will continue to manage its cash burn to extend its operational runway into the second quarter of 2025.

Key Dates

Keywords

Galera Therapeutics, avasopasem, rucosopasem, FDA, clinical trials, strategic alternatives, workforce reduction, radiotherapy, cancer, financial results, Complete Response Letter, net loss, cash runway